Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Dr. Sukhbinder Dhesy-Thind Juravinski Cancer Centre 699 Concession Street Hamilton, ON, L8V 5C2 Telephone: 905-387-9495 x64602 Fax: 905-575-6326 E-mail: [email protected] Dr. Michael McLean Editor-In-Chief Current Oncology Princess Margaret Hospital 610 University Avenue Toronto, ON, M5G 2M9 RE: Submitted manuscript “Generalizability of toxicity data from oncology clinical trials to clinical practice: Toxicity of irinotecan-based regimens in patients with metastatic colorectal cancer” Dear Editor, Please find enclosed our manuscript “Generalizability of toxicity data from oncology clinical trials to clinical practice: Toxicity of irinotecan-based regimens in patients with metastatic colorectal cancer” for submission to your respected journal. This is an original article that has not been published and is not being considered for publication elsewhere. We feel our article is suitable for publication in Current Oncology. Our article would be of significant interest to your readers given the overall importance of our results. We have determined that the toxicity rates of chemotherapy administered to non-trial patients are not significantly different compared to those quoted in published clinical trials. This provides further evidence for the generalizability of clinical trial results to clinical practice. All four authors declare that we have read and approved the submitted manuscript. The authors also declare that we do not have any competing interests. Thank you for your attention. Sincerely, Dr. Vincent Tam Dr. Sara Rask Dr. Tulay Koru-Sengul Dr. Sukhbinder Dhesy-Thind